Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 1981Cancer

A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

DSDavid J. ShilingUniversity of California, IrvineRSR. C. StillmanLawrence Livermore National SecurityACAlfred E. ChangUniversity of Michigan

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Shiling et al. (1981) studied this question.

synapsesocial.com/papers/6a7091b0e71d69abee08b2fdhttps://doi.org/10.1002/1097-0142(19810401)47:7<1746::aid-cncr2820470704>3.0.co;2-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Delta-9-Tetrahydrocannabinol as an Antiemetic in Cancer Patients Receiving High-Dose Methotrexate1979 · 258 citations
  2. 2Δ9-Tetrahydrocannabinol for Refractory Vomiting Induced by Cancer Chemotherapy1980 · 64 citations
  3. 3Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy1975 · 361 citations
  4. 4Delta-9-Tetrahydrocannabinol as an Antiemetic for Patients Receiving Cancer Chemotherapy1979 · 202 citations